Clinical Trial Update: A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg) [Phase 4]

View source ↗

Summary

A Phase 4 trial compared Combivent UDV (ipratropium bromide 500 mcg plus salbutamol 2.5 mg) to Salbutamol UDV alone in asthma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Combivent UDV (ipratropium bromide; salbutamol)
• Salbutamol UDV (salbutamol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 4 | Status: COMPLETED